Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18905972 | 0.84 | THRB (0.31) | — | |
| SCHEMBL17468807 | 0.81 | MAPT (0.39) | MAPTSMN1; SMN2ALDH1A1TP53NPC1 | |
| SCHEMBL8038928 | 0.81 | KMT2A (0.34) | ALDH1A1 | |
| SCHEMBL8050376 | 0.79 | AKR1B1 (0.43) | MAPTALDH1A1KDM4E | |
| SCHEMBL8038799 | 0.77 | ALDH1A1 (0.34) | MAPTALDH1A1 | |
| SCHEMBL8049797 | 0.77 | HTT (0.35) | MAPTSMN1; SMN2ALDH1A1KDM4ETP53 | |
| SCHEMBL8051660 | 0.74 | CYP1A2 (0.43) | MAPTSMN1; SMN2ALDH1A1KDM4ETP53 | |
| SCHEMBL8049471 | 0.74 | MAPT (0.33) | MAPTSMN1; SMN2ALDH1A1TP53NPC1 | |
| SCHEMBL8054106 | 0.71 | CYP1A2 (0.36) | ALDH1A1NPC1GAA | |
| SCHEMBL8485908 | 0.69 | PSMB8 (0.42) | MAPTALDH1A1LMNATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2141150-B1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| EP-2141150-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141150-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-0502473-B1 | Microbicidal benzo-1,2,3-thiadiazole derivatives | NOVARTIS AG (CH) | 2000-04-26 | — | — | EP | disclosed |
| US-5384321-A | Benzothiadiazole compounds | CIBA-GEIGY CORPORATION (US) | 1995-01-24 | — | — | US | disclosed |
| US-5304652-A | Benzo-1,2,3-thiadiazole derivatives; fungicides | CIBA-GEIGY CORPORATION (US) | 1994-04-19 | — | — | US | disclosed |
| EP-0420803-B1 | Benzo-1,2,3-thiadiazole derivatives and their use for protecting plants against diseases | CIBA GEIGY AG (CH) | 1994-03-09 | — | — | EP | disclosed |
| US-5260423-A | Fungicide, viricide or bactericide | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| US-5229384-A | Microbiocides | CIBA-GEIGY CORPORATION (US) | 1993-07-20 | — | — | US | disclosed |
| EP-0502473-A1 | Microbicidal benzo-1,2,3-thiadiazole derivatives | CIBA-GEIGY AG (CH) | 1992-09-09 | — | — | EP | disclosed |
| EP-0420803-A2 | Benzo-1,2,3-thiadiazole derivatives and their use for protecting plants against diseases | CIBA-GEIGY AG (CH) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | APOBEC3G 3209/4885PDCD1 4552/4885CD274 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.